Please ensure Javascript is enabled for purposes of website accessibility

This News Caused TransEnterix's Stock to Spike

By Brian Feroldi - Dec 18, 2017 at 10:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders cheer after the company announces that it has found a way to monetize its SurgiBot system.

What happened

After announcing that it is selling its SurgiBot assets to a Chinese-based medical equipment provider, shares of TransEnterix (ASXC -4.04%), a company focused on robotic surgery, rose as much as 12% in early morning trading on Monday. The rally has since cooled off but shares were still up about 5% as of 10:25 a.m. EST. 

So what

TransEnterix announced today that it is transferring ownership of the SurgiBot to Great Belief International Limited (GBIL).

Here are the key takeaways from the deal:

  • GBIL will be responsible for manufacturing the system in China and will also be on the hook for obtaining regulatory approval. GBIL has already signed a distribution agreement with China National Scientific and Instruments and Materials Company to assist with the system's commercialization.
  • TransEnterix will receive at least $29 million in total from the transaction.
  • The first payment of $7.5 million will be received before the end of 2017 and another $7.5 million is expected by the end of March of 2018. This includes a $3 million equity investment in TransEnterix's stock at a price of $2.33 per share. That represents a 15% premium to Friday's closing price.
  • The remaining $14 million in capital represents minimum royalty payments. Payment will be due once the SurgiBot System gains regulatory approval in China or in five years, whichever comes first.
  • TransEnterix will retain the option to distribute (or co-distribute) the SurgiBot outside of China.

Here what TransEnterix's CEO Todd Pope had to say about this deal:

The relationship announced today with GBIL will allow us to advance the SurgiBot System toward global commercialization while significantly reducing our required investment and simultaneously leveraging 'in-country' manufacturing in the world's most populous country. This is a strong validation of the value of the SurgiBot platform.

Given the news, it isn't hard to figure out why shares are up today.

Businessmen looking over a contract.

Image source: Getty Images.

Now what

Once upon a time, the SurgiBot System was the main reason to own TransEnterix's stocks. However, that all changed in 2016 when the FDA rejected SurgiBot because it failed to show a "substantial equivalence" to an already legally approved medical device. In response, management was forced to throw all of its weight behind Senhance since it lacked the resources (and time) to continue developing both systems.

Fast forward to today and TransEnterix is in a much better place. The Senhance system went on to win FDA approval (and even recorded its first U.S. sale) and TransEnterix's balance sheet is in good shape thanks to a recent capital raise. Adding another $29 million to the mix only increases the company's financial flexibility in its fight against Intuitive Surgical

That's all great, but the bull case for owning TransEnterix's stock from here still hinges on a successful launch of the Senhance system. On that front, I think it is still way too early to draw any real conclusions. That's why I continue to believe that caution is warranted.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
$0.38 (-4.04%) $0.02
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$206.10 (2.69%) $5.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.